Traws Pharma, Inc.
TRAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001130598
No open-market purchases or sales by Traws Pharma, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $5.19M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Traws Pharma, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 34 | 28 | −6 |
| Shares | 2.41M | 1.95M | −453.7K (−18.8%) |
| Value | $6.14M | $3.60M | −$2.54M (−41.4%) |
New holders (2)
Institutions that held Traws Pharma, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| JPMorgan Chase & Co | 4,813 | $9.00K | 0.00% |
| Hantz Financial Services, Inc. | 46 | $0 | 0.00% |
Sold out (8)
Institutions that held Traws Pharma, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Anson Funds Management LP | 145,290 | $370.0K |
| Hudson Bay Capital Management LP | 90,922 | $232.0K |
| Gsa Capital Partners LLP | 57,799 | $147.0K |
| Citadel Advisors LLC | 40,626 | $104.0K |
| Jump Financial, LLC | 23,182 | $59.0K |
| Virtu Financial LLC | 12,030 | $31.0K |
| Rockefeller Capital Management L.P. | 400 | $1.00K |
| Advisor Group Holdings, Inc. | 4 | $0 |